迈科康生物 迈科康生物

CN

We focus on the R&D and production of innovative vaccines and new adjuvants.

about

mAXVAX

We focus on the R&D and production of innovative vaccines and new adjuvants.

Maxvax Biotechnology was founded by Dr. Dexiang Chen in 2016 in China's south-western city of Chengdu. We are a global biopharmaceutical enterprise dedicated to the research, development, production and commercialization of innovative vaccines and new adjuvants.
More

Technology

& production

We provide customers with high-quality, safe
and innovative products.

Technology Platform

Maxvax has pioneered three technological platforms: recombinant protein, adjuvants, and mRNA, aimed at treating infectious diseases, cancer, and allergies.

Learn more

Technology
Platform

+

Pipeline Introduction

Utilizing our technology platforms, we have developed a diverse pipeline of prophylactic and therapeutic vaccines to combat global health burdens.

Learn more

Pipeline
Introduction

+

Production Capability

We have constructed over 200,000 sq ft of state-of-the-art R&D and manufacturing facilities to support our pipeline, enabling us to handle product development all the way to industrial scale manufacturing, all in-house.

Learn more...

Production
Capability

+

news

center

Maxvax Newsletters

  • 312025.10

    Financing Progress | Maxvax Completes Series D Financing, Raising Over RMB 400M

    Maxvax announced on October 31, 2025 the successful completion of its Series D financing round, raising over RMB 400 million. This round was jointly invested by IDG Capital, Shenzhen Capital Group (SCGC), and Ruipu Pharma. The funds will primarily support the clinical trials and commercialization preparation of Maxvax’s recombinant shingles (herpes zoster) vaccine, the Phase III clinical trial of its recombinant respiratory syncytial virus (RSV) vaccine, and preclinical research for multiple innovative vaccine candidates and international collaborations.

    more >

  • 222025.10

    Maxvax Launches Phase III Clinical Trial for Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell)

    On October 22, 2025, Maxvax Biotechnology Co., Ltd. (“Maxvax”) announced that its wholly owned subsidiary, Shanghai Maxvax Biotechnology Co., Ltd., has officially initiated the Phase III clinical trial for its Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell). The first group of participants has been successfully enrolled in Xianning, Hubei Province.

    more >

  • 162025.10

    Maxvax’s Adjuvanted Recombinant Herpes Zoster Vaccine (CHO Cell) Registration Application Accepted

    Recently, the registration application for the Adjuvanted Recombinant Herpes Zoster Vaccine (CHO Cell) independently developed by Shanghai Maxvax Biotechnology has been officially accepted by Chinese national regulatory authorities(Acceptance No. CXSS2500114).

    more >
See more

contact

mAXVAX

We are here if you have any questions and needs.

  • Contact Us

  • Opportunities

  • Branches